Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis.

Blood Neoplasia · 2025 · PMC12432457 · PMID 40948663

Europe PMC DOI

hedged sentence

0.3000

closest p · 6.0× alpha

0.3000

boldest claim

The sentences

did not reach statistical significanceP = .3not close (p > 0.1)

Patients with +1q had a numerically shorter median PFS of 17.0 months (95% CI, 10.2 to NR) as opposed to 25 months (95% CI, 13.3 to NR) in those without +1q, but this did not reach statistical significance (log rank P = .3).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.